Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Unicycive Therapeutics (UNCY) Accumulated Depreciation & Amortization (2021 - 2026)

Unicycive Therapeutics filings provide 4 years of Accumulated Depreciation & Amortization readings, the most recent being $39000.0 for Q4 2024.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 143.75% to $39000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $39000.0, a 143.75% increase, with the full-year FY2024 number at $39000.0, up 143.75% from a year prior.
  • Accumulated Depreciation & Amortization hit $39000.0 in Q4 2024 for Unicycive Therapeutics, up from $31000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $468000.0 in Q4 2021 to a low of $3000.0 in Q1 2022.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $16000.0 (2023), compared with a mean of $82538.5.
  • The widest YoY moves for Accumulated Depreciation & Amortization: up 200.0% in 2023, down 96.26% in 2023.
  • Unicycive Therapeutics' Accumulated Depreciation & Amortization stood at $468000.0 in 2021, then decreased by 8.55% to $428000.0 in 2022, then plummeted by 96.26% to $16000.0 in 2023, then soared by 143.75% to $39000.0 in 2024.
  • The last three reported values for Accumulated Depreciation & Amortization were $39000.0 (Q4 2024), $31000.0 (Q3 2024), and $25000.0 (Q2 2024) per Business Quant data.